Should I buy or sell Veradigm stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veradigm in the last year. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" MDRX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MDRX, but not buy additional shares or sell existing shares. View MDRX analyst ratings or view top-rated stocks .

What is Veradigm's stock price target for 2024?

5 brokerages have issued 12-month price objectives for Veradigm's shares. Their MDRX share price targets range from $10.00 to $13.00. On average, they predict the company's stock price to reach $11.25 in the next twelve months. This suggests a possible upside of 48.0% from the stock's current price. View analysts price targets for MDRX or view top-rated stocks among Wall Street analysts .

How have MDRX shares performed in 2024?

Veradigm's stock was trading at $10.49 at the beginning of the year. Since then, MDRX shares have decreased by 27.6% and is now trading at $7.60. View the best growth stocks for 2024 here .

How were Veradigm's earnings last quarter?

Veradigm Inc. (NASDAQ:MDRX) released its earnings results on Thursday, November, 4th. The software maker reported $0.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.18 by $0.09. The software maker earned $369 million during the quarter, compared to analyst estimates of $376.09 million. Veradigm's revenue was down 8.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.15 earnings per share.

What ETFs hold Veradigm's stock?

ETFs with the largest weight of Veradigm (NASDAQ:MDRX) stock in their portfolio include Global X Telemedicine & Digital Health ETF (EDOC) . Fidelity Digital Health ETF (FDHT) .

What is Paul Black's approval rating as Veradigm's CEO?

796 employees have rated Veradigm Chief Executive Officer Paul Black on Glassdoor.com . Paul Black has an approval rating of 65% among the company's employees.

What other stocks do shareholders of Veradigm own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Veradigm investors own include Advanced Micro Devices (AMD) , Netflix (NFLX) , Energy Transfer (ET) , CVS Health (CVS) , Ford Motor (F) , Himax Technologies (HIMX) , Intel (INTC) , OPKO Health (OPK) , Tesla (TSLA) and Activision Blizzard (ATVI) .

Who are Veradigm's major shareholders?

Veradigm's stock is owned by a variety of institutional and retail investors. Top institutional investors include Meadow Creek Wealth Advisors LLC (0.01%). Insiders that own company stock include David B Stevens, Elaina Shekhter, Elizabeth Ann Altman , Greg Garrison , Leah Jones, Lisa Khorey , Michael Klayko , Paul Black , Richard J Poulton , Tejal Vakharia and Thomas Langan. View institutional ownership trends .

How do I buy shares of Veradigm?

Shares of MDRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Does Veradigm have any subsidiaries?

The following companies are subsidiares of Veradigm: HealthGrid, Practice Fusion, and ZappRx. Read More

NASDAQ:MDRX

Veradigm (MDRX) Stock Price, News & Analysis

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)

Free MDRX Stock Alerts

$7.60

+0.05 (+0.66%)

(As of 04/19/2024 ET)

Compare

Today's Range: $7.50
▼
$8.38
50-Day Range: $6.13
▼
$8.63
52-Week Range: $5.01
▼
$14.09

Volume: 104,811 shs
Average Volume: 3.98 million shs
Market Capitalization: $830.38 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $11.25

Get Veradigm alerts:

Veradigm MarketRank™ Stock Analysis

Analyst Rating: Hold
2.20 Rating Score
Upside/Downside: 48.0% Upside
$11.25 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: -0.62
Upright™ Environmental Score
News Sentiment: 0.93
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 11.43%
From $0.70 to $0.78 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.41 out of 5 stars

Business Services Sector

187th out of 305 stocks

Computer Integrated Systems Design Industry

16th out of 34 stocks

3.1

Analyst's Opinion

Consensus Rating
Veradigm has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 1 buy rating, 4 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Veradigm has only been the subject of 1 research reports in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for MDRX.

0.0

Dividend Strength

Dividend Yield
Veradigm does not currently pay a dividend.
Dividend Growth
Veradigm does not have a long track record of dividend growth.

4.1

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Veradigm has received a 59.51% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Computerized clinical decision support software", "Personal health record software", and "Documentation software for clinicians" products. See details.
Environmental Sustainability
The Environmental Impact score for Veradigm is -0.62.

3.3

News and Social Media Coverage

News Sentiment
Veradigm has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Business Services companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Veradigm this week, compared to 3 articles on an average week.
MarketBeat Follows
3 people have added Veradigm to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Veradigm insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 2.29% of the stock of Veradigm is held by insiders.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Veradigm are expected to grow by 11.43% in the coming year, from $0.70 to $0.78 per share.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Veradigm Stock (NASDAQ:MDRX)

Veradigm Inc., a healthcare technology company, provides information technology solutions and services to healthcare organizations in the United States, Canada, and internationally. It offers electronic health records (EHR), information connectivity, private cloud hosting, outsourcing, analytics, patient access, and population health management solutions. The company operates through two segments, Hospitals and Large Physician Practices, and Veradigm. The Hospitals and Large Physician Practices segment provides integrated clinical and financial management solutions, which primarily include EHR-related software; and related installation, support and maintenance, outsourcing, private cloud hosting, and revenue cycle management services. The Veradigm segment offers payer and life sciences solutions, which are primarily targeted at payers, life sciences companies, and other healthcare stakeholders; and software applications for patient engagement and EHR software to single-specialty, and small and mid-sized physician practices, including related clinical, financial, administrative, and operational solutions. Its solutions enable clients to transition, analyze, and coordinate care, and enhance the healthcare delivery across the care community. The company serves physicians, hospitals, governments and militaries, health systems, health plans, life-sciences companies, retail clinics, surgery centers, retail pharmacies, pharmacy benefit managers, insurance companies, employer wellness clinics, consumers, lab companies, urgent care facilities, and venture capital firms, as well as post-acute organizations, such as home health and hospice agencies. The company was formerly known as Allscripts Healthcare Solutions, Inc. and changed its name to Veradigm Inc. in January 2023. Veradigm Inc. was founded in 1986 and is headquartered in Chicago, Illinois.

MDRX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

MDRX Stock News Headlines

April 19, 2024 | americanbankingnews.com

Veradigm (NASDAQ:MDRX) Shares Gap Up to $7.45

April 15, 2024 | americanbankingnews.com

StockNews.com Begins Coverage on Veradigm (NASDAQ:MDRX)

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 12, 2024 | americanbankingnews.com

Veradigm (NASDAQ:MDRX) Shares Gap Up to $8.00

April 12, 2024 | americanbankingnews.com

Veradigm Inc. (NASDAQ:MDRX) Given Average Rating of "Hold" by Brokerages

April 9, 2024 | businesswire.com

Veradigm Network Solution Practice Fusion EHR Receives Top Ambulatory Rankings

April 3, 2024 | businesswire.com

Veradigm and Vim to Improve Payer-Provider Collaboration

March 26, 2024 | prnewswire.com

Update in Lawsuit for Investors who purchased shares of Veradigm Inc. (NASDAQ: MDRX) announced by the Shareholders Foundation

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 19, 2024 | markets.businessinsider.com

Veradigm’s Challenging Outlook: Hold Rating Justified Amid Revenue Growth, Margin Pressures, and Audit Concerns

March 16, 2024 | finance.yahoo.com

MDRX Apr 2024 2.500 put

March 14, 2024 | finance.yahoo.com

Veradigm to Participate in KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

March 13, 2024 | msn.com

Veradigm reports initial financial outlook for fiscal 2024

March 13, 2024 | finance.yahoo.com

Veradigm Announces Initial Financial Guidance for Fiscal 2024

March 4, 2024 | finance.yahoo.com

Veradigm Completes Acquisition of ScienceIO

March 4, 2024 | finance.yahoo.com

Veradigm to Participate in Barclays 26th Annual Global Healthcare Conference

February 28, 2024 | benzinga.com

Market Whales and Their Recent Bets on MDRX Options

February 28, 2024 | businesswire.com

Veradigm to Participate in TD Cowen Annual Health Care Conference

February 28, 2024 | businesswire.com

Veradigm Receives Expected Delisting Notice from Nasdaq

February 27, 2024 | finance.yahoo.com

Veradigm Inc (MDRX) Announces Strategic Acquisition of ScienceIO to Enhance AI Capabilities

February 27, 2024 | businesswire.com

Veradigm to Acquire ScienceIO

February 27, 2024 | businesswire.com

Veradigm Provides Update on its Financial Restatement Process

February 22, 2024 | finance.yahoo.com

Veradigm to Highlight New EHR-Integrated Care Gap Alert Solution at ViVE 2024 Conference

February 22, 2024 | businesswire.com

Veradigm to Highlight New EHR-Integrated Care Gap Alert Solution at ViVE 2024 Conference

February 20, 2024 | finance.yahoo.com

Veradigm Reveals New Insights on the Prevalence of Cardiovascular Conditions in the U.S.

February 20, 2024 | businesswire.com

Veradigm Reveals New Insights on the Prevalence of Cardiovascular Conditions in the U.S.

February 13, 2024 | finance.yahoo.com

Veradigm and American College of Cardiology Launch Influenza Vaccination Education Initiative to Improve Cardiovascular Health

See More Headlines

Receive MDRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Veradigm and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/04/2021
Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Business Services
Industry: Computer integrated systems design
Sub-Industry: Health Care Technology
Current Symbol: NASDAQ:MDRX
CUSIP: 01988P10
CIK: 1124804
Web: www.allscripts.com
Phone: (800) 334-8534
Fax: 313-322-9600
Employees: 8,000
Year Founded: 1986

Price Target and Rating

Average Stock Price Target: $11.25
High Stock Price Target: $13.00
Low Stock Price Target: $10.00
Potential Upside/Downside: +36.4%
Consensus Rating: Hold
Rating Score (0-4): 2.20
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: $1.53 billion
Price / Sales: 0.59
Cash Flow: $3.01 per share
Price / Cash Flow: 2.74
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: 109,260,000
Free Float: 106,758,000
Market Cap: $901.40 million
Optionable: Optionable
Beta: 0.65

Social Links

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

Mr. P. Gregory Garrison (Age 70)
Executive Chairman of the Board
Comp: $103k
Ms. Tejal Vakharia (Age 50)
Senior VP of Marketing & Government Affairs, General Counsel and Chief Compliance Counsel
Comp: $1.04M
Dr. Shih-Yin Ho M.B.A. (Age 53)
M.D., Interim Chief Executive Officer & Director
Mr. Thomas J. Langan (Age 57)
President & Chief Commercial Officer
Mr. Leland A. Westerfield (Age 54)
Interim CFO and Principal Financial & Accounting Officer
Jenny Gelinas
Vice President of Investor Relations
Mr. Richard Elmore
Senior Vice President of Corporate Development & Strategy
Ms. Lisa Hammond C.P.C. (Age 51)
Senior VP & Chief Human Resources Officer
Mr. John Sage
Senior Vice President of U.S. Hospitals & Health Systems Sales
Mr. Elliot Bryant
Senior VP & General Manager for Classic Client Solutions Business Unit

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

MDRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Veradigm stock right now?: 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veradigm in the last year. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" MDRX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MDRX, but not buy additional shares or sell existing shares.
View MDRX analyst ratings or view top-rated stocks.
What is Veradigm's stock price target for 2024?: 5 brokerages have issued 12-month price objectives for Veradigm's shares. Their MDRX share price targets range from $10.00 to $13.00. On average, they predict the company's stock price to reach $11.25 in the next twelve months. This suggests a possible upside of 48.0% from the stock's current price.
View analysts price targets for MDRX or view top-rated stocks among Wall Street analysts.
How have MDRX shares performed in 2024?: Veradigm's stock was trading at $10.49 at the beginning of the year. Since then, MDRX shares have decreased by 27.6% and is now trading at $7.60.
View the best growth stocks for 2024 here.
How were Veradigm's earnings last quarter?: Veradigm Inc. (NASDAQ:MDRX) released its earnings results on Thursday, November, 4th. The software maker reported $0.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.18 by $0.09. The software maker earned $369 million during the quarter, compared to analyst estimates of $376.09 million. Veradigm's revenue was down 8.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.15 earnings per share.
What ETFs hold Veradigm's stock?: ETFs with the largest weight of Veradigm (NASDAQ:MDRX) stock in their portfolio include Global X Telemedicine & Digital Health ETF (EDOC).Fidelity Digital Health ETF (FDHT).
What is Paul Black's approval rating as Veradigm's CEO?: 796 employees have rated Veradigm Chief Executive Officer Paul Black on Glassdoor.com. Paul Black has an approval rating of 65% among the company's employees.

What other stocks do shareholders of Veradigm own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Veradigm investors own include Advanced Micro Devices (AMD), Netflix (NFLX), Energy Transfer (ET), CVS Health (CVS), Ford Motor (F), Himax Technologies (HIMX), Intel (INTC), OPKO Health (OPK), Tesla (TSLA) and Activision Blizzard (ATVI).
Who are Veradigm's major shareholders?: Veradigm's stock is owned by a variety of institutional and retail investors. Top institutional investors include Meadow Creek Wealth Advisors LLC (0.01%). Insiders that own company stock include David B Stevens, Elaina Shekhter, Elizabeth Ann Altman, Greg Garrison, Leah Jones, Lisa Khorey, Michael Klayko, Paul Black, Richard J Poulton, Tejal Vakharia and Thomas Langan.
View institutional ownership trends.
How do I buy shares of Veradigm?: Shares of MDRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.
Does Veradigm have any subsidiaries?: The following companies are subsidiares of Veradigm: HealthGrid, Practice Fusion, and ZappRx.
Read More

This page (NASDAQ:MDRX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Veradigm (MDRX) Stock Price, News & Analysis

Veradigm MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Consensus Rating

Amount of Analyst Coverage

Short Interest

Short Interest

Dividend Strength

Dividend Yield

Dividend Growth

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

MarketBeat Follows

Company Ownership

Insider Buying vs. Insider Selling

Percentage Held by Insiders

Earnings and Valuation

Earnings Growth

About Veradigm Stock (NASDAQ:MDRX)

MDRX Stock Price History

MDRX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Institutional Ownership

MDRX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™